JP2020511512A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511512A5 JP2020511512A5 JP2019552088A JP2019552088A JP2020511512A5 JP 2020511512 A5 JP2020511512 A5 JP 2020511512A5 JP 2019552088 A JP2019552088 A JP 2019552088A JP 2019552088 A JP2019552088 A JP 2019552088A JP 2020511512 A5 JP2020511512 A5 JP 2020511512A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- alkyl
- alkynyl
- alkenyl
- epoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 20
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 15
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 15
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 15
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 15
- 125000000304 alkynyl group Chemical group 0.000 claims 11
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 10
- 239000004593 Epoxy Substances 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 8
- -1 2-Methylbutanoyl Chemical group 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 238000002347 injection Methods 0.000 claims 5
- 239000007924 injection Substances 0.000 claims 5
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 claims 4
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000005024 alkenyl aryl group Chemical group 0.000 claims 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims 3
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 3
- 230000000981 bystander Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 102000002698 KIR Receptors Human genes 0.000 claims 2
- 108010043610 KIR Receptors Proteins 0.000 claims 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 2
- 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 2
- 125000005025 alkynylaryl group Chemical group 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000002601 intratumoral effect Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 229940123965 Immunoglobulin inhibitor Drugs 0.000 claims 1
- 240000000233 Melia azedarach Species 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000006193 alkinyl group Chemical group 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 230000007969 cellular immunity Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017901027 | 2017-03-23 | ||
| AU2017901027A AU2017901027A0 (en) | 2017-03-23 | Combination Therapy | |
| PCT/AU2018/050277 WO2018170559A1 (en) | 2017-03-23 | 2018-03-23 | Combination therapy for the treatment or prevention of tumours |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511512A JP2020511512A (ja) | 2020-04-16 |
| JP2020511512A5 true JP2020511512A5 (https=) | 2020-10-08 |
| JP6905075B2 JP6905075B2 (ja) | 2021-07-21 |
Family
ID=63583892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019552088A Active JP6905075B2 (ja) | 2017-03-23 | 2018-03-23 | 腫瘍の治療または予防のための併用療法 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11213506B2 (https=) |
| EP (1) | EP3600281B1 (https=) |
| JP (1) | JP6905075B2 (https=) |
| KR (1) | KR102228055B1 (https=) |
| CN (1) | CN110461324A (https=) |
| AU (1) | AU2018238202C1 (https=) |
| CA (1) | CA3056685C (https=) |
| DK (1) | DK3600281T3 (https=) |
| EA (1) | EA201992220A1 (https=) |
| ES (1) | ES2953575T3 (https=) |
| FI (1) | FI3600281T3 (https=) |
| HR (1) | HRP20230936T1 (https=) |
| HU (1) | HUE063299T2 (https=) |
| IL (1) | IL269522B2 (https=) |
| LT (1) | LT3600281T (https=) |
| MX (1) | MX391826B (https=) |
| MY (1) | MY197427A (https=) |
| PH (1) | PH12019502132A1 (https=) |
| PL (1) | PL3600281T3 (https=) |
| PT (1) | PT3600281T (https=) |
| RS (1) | RS64472B1 (https=) |
| SG (1) | SG11201907891XA (https=) |
| SI (1) | SI3600281T1 (https=) |
| SM (1) | SMT202300272T1 (https=) |
| UA (1) | UA125614C2 (https=) |
| WO (1) | WO2018170559A1 (https=) |
| ZA (1) | ZA201906001B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006326872C1 (en) * | 2005-12-23 | 2018-05-17 | QBiotics Pty Ltd | Tiglien-3-one derivatives |
| TWI707038B (zh) | 2013-08-05 | 2020-10-11 | 美商扭轉生物科技有限公司 | 重新合成之基因庫 |
| WO2016126882A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| US9981239B2 (en) | 2015-04-21 | 2018-05-29 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| KR20180050411A (ko) | 2015-09-18 | 2018-05-14 | 트위스트 바이오사이언스 코포레이션 | 올리고핵산 변이체 라이브러리 및 그의 합성 |
| KR102794025B1 (ko) | 2015-09-22 | 2025-04-09 | 트위스트 바이오사이언스 코포레이션 | 핵산 합성을 위한 가요성 기판 |
| US10417457B2 (en) | 2016-09-21 | 2019-09-17 | Twist Bioscience Corporation | Nucleic acid based data storage |
| CN110892485B (zh) | 2017-02-22 | 2024-03-22 | 特韦斯特生物科学公司 | 基于核酸的数据存储 |
| US10696965B2 (en) | 2017-06-12 | 2020-06-30 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| CN111566125A (zh) | 2017-09-11 | 2020-08-21 | 特韦斯特生物科学公司 | Gpcr结合蛋白及其合成 |
| CN111565834B (zh) | 2017-10-20 | 2022-08-26 | 特韦斯特生物科学公司 | 用于多核苷酸合成的加热的纳米孔 |
| KR102804057B1 (ko) | 2018-01-04 | 2025-05-07 | 트위스트 바이오사이언스 코포레이션 | Dna 기반 디지털 정보 저장 |
| CA3100739A1 (en) | 2018-05-18 | 2019-11-21 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
| US12357959B2 (en) | 2018-12-26 | 2025-07-15 | Twist Bioscience Corporation | Highly accurate de novo polynucleotide synthesis |
| CA3131691A1 (en) | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
| CN113766930B (zh) | 2019-02-26 | 2025-07-22 | 特韦斯特生物科学公司 | Glp1受体的变异核酸文库 |
| EP3952858B1 (en) * | 2019-04-12 | 2025-12-17 | QBiotics Pty Ltd | Method of treating tumours |
| MX2021015673A (es) | 2019-06-19 | 2022-02-03 | QBiotics Pty Ltd | Alteracion de biopelicula. |
| AU2020298294A1 (en) | 2019-06-21 | 2022-02-17 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| JP2022548309A (ja) | 2019-09-23 | 2022-11-17 | ツイスト バイオサイエンス コーポレーション | Ｃｒｔｈ２のバリアント核酸ライブラリー |
| WO2021061842A1 (en) | 2019-09-23 | 2021-04-01 | Twist Bioscience Corporation | Variant nucleic acid libraries for single domain antibodies |
| IL293670A (en) | 2019-12-09 | 2022-08-01 | Twist Bioscience Corp | Variable nucleic acid libraries for adenosine receptors |
| WO2022159620A1 (en) | 2021-01-21 | 2022-07-28 | Twist Bioscience Corporation | Methods and compositions relating to adenosine receptors |
| KR102774792B1 (ko) | 2021-05-06 | 2025-03-05 | 한국과학기술연구원 | 가시광선에 의해 활성화되는 항암 면역치료용 나노입자 및 이의 용도 |
| CN118451065A (zh) * | 2021-12-21 | 2024-08-06 | Q生物股份有限公司 | 结晶中间体 |
| MX2024010046A (es) * | 2022-02-17 | 2024-08-26 | QBiotics Pty Ltd | Terapias de combinacion. |
| JP2026500534A (ja) * | 2022-12-21 | 2026-01-07 | キューバイオティクス プロプライアタリー リミティド | 結晶形態及びその製造方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006268148B2 (en) * | 2005-07-13 | 2012-11-01 | Salvia Sciences, Inc. | Ester prodrugs of prostratin and related phorbol compounds |
| AU2006326872C1 (en) * | 2005-12-23 | 2018-05-17 | QBiotics Pty Ltd | Tiglien-3-one derivatives |
| RS58532B1 (sr) | 2013-04-18 | 2019-04-30 | Qbiotics Ltd | Metodi i kompozicije za zarastanje rana |
| WO2015133596A1 (ja) * | 2014-03-07 | 2015-09-11 | 国立大学法人京都大学 | 細胞培養用組成物 |
| AU2015289081B2 (en) | 2014-07-16 | 2020-02-06 | Transgene Sa | Combination of oncolytic virus with immune checkpoint modulators |
| JP6991857B2 (ja) | 2014-10-10 | 2022-01-13 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療 |
| CN104926758A (zh) * | 2015-05-22 | 2015-09-23 | 南京泽朗医药科技有限公司 | 斑籽素的制备方法及其在抗白血病药物中的应用 |
| CN108026026B (zh) * | 2015-08-03 | 2021-02-09 | 夸德里加生物科学公司 | 作为化疗剂的β-取代的β-氨基酸和类似物及其应用 |
-
2018
- 2018-03-23 DK DK18770812.8T patent/DK3600281T3/da active
- 2018-03-23 KR KR1020197031149A patent/KR102228055B1/ko active Active
- 2018-03-23 FI FIEP18770812.8T patent/FI3600281T3/fi active
- 2018-03-23 CA CA3056685A patent/CA3056685C/en active Active
- 2018-03-23 AU AU2018238202A patent/AU2018238202C1/en active Active
- 2018-03-23 MY MYPI2019005163A patent/MY197427A/en unknown
- 2018-03-23 SG SG11201907891XA patent/SG11201907891XA/en unknown
- 2018-03-23 LT LTEPPCT/AU2018/050277T patent/LT3600281T/lt unknown
- 2018-03-23 HR HRP20230936TT patent/HRP20230936T1/hr unknown
- 2018-03-23 RS RS20230697A patent/RS64472B1/sr unknown
- 2018-03-23 SI SI201830978T patent/SI3600281T1/sl unknown
- 2018-03-23 WO PCT/AU2018/050277 patent/WO2018170559A1/en not_active Ceased
- 2018-03-23 HU HUE18770812A patent/HUE063299T2/hu unknown
- 2018-03-23 CN CN201880019617.4A patent/CN110461324A/zh active Pending
- 2018-03-23 JP JP2019552088A patent/JP6905075B2/ja active Active
- 2018-03-23 PT PT187708128T patent/PT3600281T/pt unknown
- 2018-03-23 EP EP18770812.8A patent/EP3600281B1/en active Active
- 2018-03-23 UA UAA201910449A patent/UA125614C2/uk unknown
- 2018-03-23 IL IL269522A patent/IL269522B2/en unknown
- 2018-03-23 PL PL18770812.8T patent/PL3600281T3/pl unknown
- 2018-03-23 SM SM20230272T patent/SMT202300272T1/it unknown
- 2018-03-23 MX MX2019011221A patent/MX391826B/es unknown
- 2018-03-23 EA EA201992220A patent/EA201992220A1/ru unknown
- 2018-03-23 ES ES18770812T patent/ES2953575T3/es active Active
- 2018-03-23 US US16/496,333 patent/US11213506B2/en active Active
-
2019
- 2019-09-11 ZA ZA2019/06001A patent/ZA201906001B/en unknown
- 2019-09-17 PH PH12019502132A patent/PH12019502132A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511512A5 (https=) | ||
| HRP20230936T1 (hr) | Kombinirana terapija za liječenje ili prevenciju tumora | |
| ES2902360T3 (es) | Inhibidores de PD-1/PD-L1 | |
| JP2019510004A5 (https=) | ||
| JP2021530487A5 (https=) | ||
| IL275649B2 (en) | Irak degraders and uses thereof | |
| JP2013544846A5 (https=) | ||
| JP2019533458A5 (https=) | ||
| JP2020506951A5 (https=) | ||
| KR20180100539A (ko) | 치료용 조성물, 병용 및 적용과 관련된 사용방법 | |
| JP2018506550A5 (https=) | ||
| JP2016510030A5 (https=) | ||
| JP2018517686A5 (https=) | ||
| AR031364A1 (es) | Agonistas del receptor adrenergico beta-2, una composicion farmaceutica, uso de dichos agonistas para la manufactura de un medicamento, un metodo para identificar compuestos de ligando multimerico que poseen propiedades de enlace multimerico, y un centro de compuestos de ligando multimerico que pose | |
| JP2009536650A5 (https=) | ||
| JP2018511628A5 (https=) | ||
| JPWO2020093061A5 (https=) | ||
| JP2019524791A5 (https=) | ||
| RU2020109775A (ru) | Комплексная терапия | |
| KR102826380B1 (ko) | 카이네이스 저해제의 결정질 염 형태 | |
| JP2015536997A5 (https=) | ||
| JP2008506710A5 (https=) | ||
| JP2020531414A5 (https=) | ||
| RU2017129151A (ru) | Производное резорцина в качестве ингибитора hsp90 | |
| JP2017531013A5 (https=) |